23,646 Shares in Pharvaris N.V. $PHVS Bought by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company acquired a new stake in shares of Pharvaris N.V. (NASDAQ:PHVS) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 23,646 shares of the company’s stock, valued at approximately $818,000.

Other institutional investors have also added to or reduced their stakes in the company. venBio Partners LLC lifted its position in shares of Pharvaris by 8.2% in the 3rd quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock worth $115,751,000 after purchasing an additional 350,000 shares during the period. Deerfield Management Company L.P. raised its stake in Pharvaris by 21.1% in the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after buying an additional 425,000 shares in the last quarter. Commodore Capital LP raised its stake in Pharvaris by 1.6% in the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock worth $54,211,000 after buying an additional 29,525 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its holdings in Pharvaris by 72.7% in the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after buying an additional 772,583 shares during the period. Finally, Wellington Management Group LLP purchased a new stake in Pharvaris in the third quarter worth about $43,282,000.

Analyst Upgrades and Downgrades

Several analysts have weighed in on PHVS shares. HSBC raised Pharvaris to an “overweight” rating in a research report on Thursday, August 13th. HC Wainwright restated a “buy” rating on shares of Pharvaris in a research note on Friday, August 14th. UBS Group set a $74.00 price target on Pharvaris in a research report on Wednesday, May 13th. Wells Fargo & Company initiated coverage on Pharvaris in a research note on Wednesday, July 15th. They issued an “overweight” rating and a $55.00 price target on the stock. Finally, Morgan Stanley increased their price objective on Pharvaris from $41.00 to $46.00 and gave the stock an “overweight” rating in a report on Thursday, June 25th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Pharvaris currently has an average rating of “Moderate Buy” and a consensus price target of $51.08.

Pharvaris Price Performance

Shares of Pharvaris stock opened at $35.25 on Friday. The stock has a market cap of $2.31 billion, a price-to-earnings ratio of -11.56 and a beta of -2.33. The firm’s 50-day moving average is $34.78 and its 200 day moving average is $31.03. Pharvaris N.V. has a 1 year low of $20.65 and a 1 year high of $38.13.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). On average, equities analysts expect that Pharvaris N.V. will post -3.15 EPS for the current fiscal year.

Insider Activity

In related news, insider Anne Lesage sold 30,703 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total transaction of $1,089,649.47. Following the completion of the sale, the insider owned 93,969 shares of the company’s stock, valued at $3,334,959.81. This trade represents a 24.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Berndt Modig sold 2,292 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $34.77, for a total transaction of $79,692.84. Following the completion of the transaction, the chief executive officer owned 130,625 shares of the company’s stock, valued at approximately $4,541,831.25. The trade was a 1.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 118,655 shares of company stock worth $4,188,002 over the last 90 days. 11.84% of the stock is currently owned by insiders.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.